Analysts have been eager to weigh in on the Healthcare sector with new ratings on Constellation Pharmaceuticals (CNST), Myovant Sciences (MYOV) and Surgalign Holdings (SRGA).
Constellation Pharmaceuticals (CNST)
In a report issued on April 15, Reni Benjamin from JMP Securities maintained a Hold rating on Constellation Pharmaceuticals. The company’s shares closed last Monday at $33.70.
According to TipRanks.com, Benjamin is ranked 0 out of 5 stars with an average return of -8.6% and a 34.4% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Bicycle Therapeutics, and Sutro Biopharma.
The word on The Street in general, suggests a Hold analyst consensus rating for Constellation Pharmaceuticals with a $39.88 average price target, which is a 18.0% upside from current levels. In a report issued on June 2, J.P. Morgan also downgraded the stock to Hold with a $34.00 price target.
See today’s analyst top recommended stocks >>
Myovant Sciences (MYOV)
JMP Securities analyst Jason Butler reiterated a Buy rating on Myovant Sciences on May 28 and set a price target of $42.00. The company’s shares closed last Monday at $23.74.
According to TipRanks.com, Butler is a 4-star analyst with an average return of 8.6% and a 45.1% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals.
Myovant Sciences has an analyst consensus of Strong Buy, with a price target consensus of $36.60, a 52.5% upside from current levels. In a report issued on May 21, Robert W. Baird also assigned a Buy rating to the stock with a $30.00 price target.
Surgalign Holdings (SRGA)
JMP Securities analyst David Turkaly reiterated a Buy rating on Surgalign Holdings on May 28 and set a price target of $4.00. The company’s shares closed last Monday at $1.70, close to its 52-week low of $1.46.
According to TipRanks.com, Turkaly is a 4-star analyst with an average return of 16.8% and a 56.6% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics.
Surgalign Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
